Anti-Notch plus endocrine therapy in ER+ breast cancer inhibits cancer stem cells by increasing DAXX

Coverage, in order

1. 2d ago
   JCI Insight indie study

   Anti-Notch plus endocrine therapy in ER+ breast cancer inhibits cancer stem cells by increasing DAXX

   Resistance to endocrine therapy (ET) in estrogen receptor–positive (ER+) breast cancer is mediated by Notch signaling, but the clinical application of anti-Notch therapy has been limited by the lack of predictive biomarkers. To identify Notch-regulated biomarkers, we conducted a presurgical window…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.